AtmosR Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$967K
- Investors
-
4
AtmosR General Information
Description
Developer of neurological disorder therapeutics designed to address severe brain conditions through protein aggregation-targeted treatment. The company develops small molecule inhibitors, blood-brain barrier therapies, neuronal restoration compounds, and proteasome-triggered degradation technologies, enabling healthcare providers to reduce neuronal toxicity and support improved cellular function, neurological stability, and therapeutic accessibility.
Contact Information
Website
www.atmosr.comCorporate Office
- Imp Des Lotiers
- 13710 Fuveau
- France
Corporate Office
- Imp Des Lotiers
- 13710 Fuveau
- France
AtmosR Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Equity Crowdfunding | 30-Apr-2025 | $967K | Completed | Generating Revenue | ||
| 4. Accelerator/Incubator | 10-Jun-2022 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Jan-2022 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Jan-2022 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 01-Jan-2022 | Completed | Generating Revenue |
AtmosR Patents
AtmosR Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024239653-A1 | Adenine derivatives as hsp90 inhibitors | Pending | 17-Mar-2023 | ||
| EP-4680606-A1 | Adenine derivatives as hsp90 inhibitors | Pending | 17-Mar-2023 | ||
| WO-2024194175-A1 | Adenine derivatives as hsp90 inhibitors | Inactive | 17-Mar-2023 | ||
| WO-2023006993-A1 | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome | Inactive | 30-Jul-2021 | A61K31/4745 |
AtmosR Signals
AtmosR Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EIT Health | Accelerator/Incubator | |||
| European Innovation Council | Accelerator/Incubator | |||
| Incubateur Impulse | Accelerator/Incubator | |||
| Neighborhood | Accelerator/Incubator |
AtmosR FAQs
-
When was AtmosR founded?
AtmosR was founded in 2019.
-
Where is AtmosR headquartered?
AtmosR is headquartered in Fuveau, France.
-
What is the size of AtmosR?
AtmosR has 9 total employees.
-
What industry is AtmosR in?
AtmosR’s primary industry is Drug Discovery.
-
Is AtmosR a private or public company?
AtmosR is a Private company.
-
What is the current valuation of AtmosR?
The current valuation of AtmosR is .
-
What is AtmosR’s current revenue?
The current revenue for AtmosR is .
-
How much funding has AtmosR raised over time?
AtmosR has raised $1.04M.
-
Who are AtmosR’s investors?
EIT Health, European Innovation Council, Incubateur Impulse, and Neighborhood have invested in AtmosR.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process